Meeting
2022 ASCO Genitourinary Cancers Symposium
The impact of baseline peripheral cytokines on survival in metastatic clear cell renal cell carcinoma (RCC) treated with nivolumab: NIVOREN GETUG-AFU 26 Translational study.
Authors
Lucia Carril
Institut Gustave Roussy, Villejuif, France
Lucia Carril , Marie Naigeon , Cécile Dalban , Aude Desnoyer , Nathalie Rioux-Leclercq , Catherine Sautes-Fridman , Maxime Meylan , Yann-Alexandre Vano , Benoit Beusenlick , Salem Chouaib , Caroline de Oliveira , Florence Tantot , Bernard Escudier , Laurence Albiges , Nathalie Chaput
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 379)
DOI
10.1200/JCO.2022.40.6_suppl.379
Abstract #
379
Poster Bd #
H11
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
NIVOREN GETUG-AFU 26 translational study: Association of PD-1, AXL, and PBRM-1 with outcomes in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N).
First Author: Yann-Alexandre Vano
Poster
2023 ASCO Genitourinary Cancers Symposium
Baseline circulating soluble factors as predictors of immune-related adverse events (irAEs) in patients (pts) with metastatic clear cell renal carcinoma (mRCC) treated with nivolumab: A translational NIVOREN GETUG-AFU 26 study.
First Author: Lucia Carril-Ajuria
Poster
2022 ASCO Genitourinary Cancers Symposium
Association of adrenal metastases with outcomes in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab in the GETUG-AFU-26 NIVOREN phase II trial.
First Author: Emilien Billon
Poster
2018 Genitourinary Cancers Symposium
A phase I/II study of sitravatinib (MGCD-516) plus nivolumab in patients (pts) with metastatic clear-cell renal cell carcinoma (ccRCC) that progressed on prior VEGF-targeted therapy.
First Author: Pavlos Msaouel